HilleVax

HilleVax was a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, most notably HIL-214, a virus-like-particle based vaccine candidate aimed at preventing moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was surfaced in the API Evangelist network as a portfolio company of Lightspeed Venture Partners. Enrichment probing found no developer program, no API, no developer portal, and no public API documentation of any kind, which is expected for a clinical-stage vaccine developer rather than a technology/API producer. The company's primary domain (hillevax.com) now redirects to xoma.com (XOMA Royalty), indicating HilleVax has been acquired and wound down as an independent operating company; XOMA Royalty itself was subsequently acquired by Ligand (closed July 2026). This profile is retained as a company/identity record with no API surface.

HilleVax is profiled on the APIs.io network. Tagged areas include Company, Biopharmaceutical, Vaccines, Life Sciences, and Healthcare.

🌐 Visit website 📡 Source on GitHub

5.7/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs

CompanyBiopharmaceuticalVaccinesLife SciencesHealthcareNorovirusClinical Stage

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 5.7/100 · minimal

Contract Quality 0.0 / 25

Developer Ergonomics 0.0 / 20

Commercial Clarity 0.0 / 20

Operational Transparency 0.0 / 13

Governance 0.0 / 12

Discoverability 6.8 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/hillevax: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Resources

Company 1

The organization behind the API

Website

Website

Source (apis.yml)

aid: hillevax
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/hillevax.png
name: HilleVax
description: HilleVax was a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines,
  most notably HIL-214, a virus-like-particle based vaccine candidate aimed at preventing moderate-to-severe acute gastroenteritis
  caused by norovirus infection. The company was surfaced in the API Evangelist network as a portfolio company of Lightspeed
  Venture Partners. Enrichment probing found no developer program, no API, no developer portal, and no public API documentation
  of any kind, which is expected for a clinical-stage vaccine developer rather than a technology/API producer. The company's
  primary domain (hillevax.com) now redirects to xoma.com (XOMA Royalty), indicating HilleVax has been acquired and wound
  down as an independent operating company; XOMA Royalty itself was subsequently acquired by Ligand (closed July 2026). This
  profile is retained as a company/identity record with no API surface.
url: https://raw.githubusercontent.com/api-evangelist/hillevax/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- lightspeed-venture-partners
x-tier: stub
x-tier-reason: no-api-surface
x-status: acquired
x-acquisition-note: hillevax.com redirects to xoma.com (XOMA Royalty); no developer/API surface exists.
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-20'
tags:
- Company
- Biopharmaceutical
- Vaccines
- Life Sciences
- Healthcare
- Norovirus
- Clinical Stage
common:
- type: Website
  url: https://www.hillevax.com
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-20'
  status: nochange
  artifacts_added: 0
  pass: local-v1